UPDATE: Piper Jaffray Lowers PT on Supernus Pharmaceuticals on Earnings - Supernus Pharmaceuticals (NASDAQ:SUPN)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Piper Jaffray analyst David Amsellem published a report on Supernus Pharmaceuticals (NASDAQ: SUPN) that reiterated its Overweight rating and lowered the price target from $15 to $14 per share.Piper Jaffray reported that, “Supernus reported a 4Q12 net loss per share of ($0.51) and finished 2012 with $92M in cash on hand. Management provided favorable color regarding the recent Oxtellar XR launch, noting particularly strong managed care access for the product. With one product now on the market and another launch (i.e., Trokendi XR, which should launch in 3Q13) on the horizon (each with sales potential in excess of $150M in our view), plus an advancing pipeline focused on ADHD/psychiatry, SUPN shares remain attractive in our view in the context of a market cap of near $200M.”Shares of Supernus Pharmaceuticals closed at $6.90 on Thursday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!